FDCC
BLFS icon

Foster Dykema Cabot & Co’s BioLife Solutions BLFS Stock Holding History

Foster Dykema Cabot & Co’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-177
Closed -$4K – 335
2023
Q2 		$4K Buy
+177
New +$3.73K ﹤0.01% 313

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Foster Dykema Cabot & Co's BLFS Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of BioLife Solutions (BLFS) in Q3 2023, closing a stake of 177 shares — an estimated $4K sold.

Foster Dykema Cabot & Co first reported a position in BLFS in Q2 2023 and held it in 1 quarter. The position peaked at $4K in Q2 2023. 153 funds tracked by Wall St. Rank hold BLFS as of Q3 2023.

  • Foster Dykema Cabot & Co reported no remaining BioLife Solutions position as of Q3 2023 after selling out during the quarter.
  • Foster Dykema Cabot & Co sold 177 BioLife Solutions shares in Q3 2023, an estimated $4K.
  • Foster Dykema Cabot & Co first reported a position in BioLife Solutions in Q2 2023 and held it in 1 quarter.
  • Foster Dykema Cabot & Co's BioLife Solutions position peaked at $4K in Q2 2023.
  • 153 funds tracked by Wall St. Rank held BioLife Solutions as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.